A randomized, open-label study in the Asia-Pacific region comparing the safety and efficacy of etanercept with usual DMARD [disease-modifying anti-rheumatic drug] therapy in subjects with rheumatoid arthritis

Trial Profile

A randomized, open-label study in the Asia-Pacific region comparing the safety and efficacy of etanercept with usual DMARD [disease-modifying anti-rheumatic drug] therapy in subjects with rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2010

At a glance

  • Drugs Etanercept (Primary) ; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms APPEAL
  • Sponsors Wyeth
  • Most Recent Events

    • 19 Jun 2010 DMARDs identified as leflunomide, hydroxychlorquine or sulfasalazine, and added as descriptors
    • 19 Jun 2010 QOL results presented at the 11th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2010 Results presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top